Abstract
Filgotinib (Jyseleca(R)) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Scienc......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
